

Minutes of the Authority meeting on 1 July 2026 held at 2 Redman Place, London

Members present	Julia Chain (Chair) Tim Child (online) Frances Flinter Tom Fowler Zeynep Gurtin Alex Kafetz	Alison McTavish Geeta Nargund (online for items 1-5) Rosamund Scott Catharine Seddon Anya Sizer Stephen Troup (online) Christine Watson
Apologies	Graham James	
Observers	Emma Heslington, Department of Health and Social Care (DHSC)	
Staff in attendance	Peter Thompson (Chief Executive) Rachel Cutting (Director of Compliance and Information) Clare Ettinghausen (Director of Strategy and Corporate Affairs) Tom Skrinar (Director of Finance, Planning and Technology) Amanda Evans (Head of Research and Intelligence) (item 8 only) Elena Corujo-Simon (Senior Research Manager) (item 8 only) Joanne Anton (Head of Policy) Annabel Salisbury (Regulatory Policy Manager) Sophie Tuhey (Head of Planning and Governance) Shabbir Qureshi (Risk and Business Planning Manager) Alison Margrave (Board Governance Manager)	

Members

There were 13 members at the meeting – 8 lay and 5 professional members.

1. Welcome, apologies and declarations of interest

- 1.1.** The Chair opened the meeting by welcoming Authority members and HFEA staff to the meeting.
- 1.2.** The Chair welcomed Emma Heslington from the Department of Health and Social Care (DHSC) to the meeting.
- 1.3.** The Chair also welcomed observers and stated that the meeting was being recorded in line with previous meetings and for reasons of transparency. The recording would be made available on the HFEA website to allow members of the public to view it.
- 1.4.** Declarations of interest were made by:
 - Steve Troup (consultancy work within the fertility sector)
 - Tim Child (consultancy work within the fertility sector overseas)
 - Anya Sizer (freelance advisory work within the fertility sector)
 - Alex Kafetz (member of The Advisory Board to the Patient Safety Commissioner and NED for Care Quality Commission (CQC))
 - Geeta Nargund (appointed as a Board Member of The Parliamentary Office of Science and Technology ([POST](#)))

2. Previous minutes and matters arising

- 2.1.** The Chair introduced the minutes from the meeting held on 20 May 2026 and thanked those members who had contributed to the minutes.
- 2.2.** The minutes of the meeting held on 20 May 2026 were agreed as a true record of the meetings and could be signed by the Chair.

Matters arising

- 2.3.** The Chair informed members that the matters arising from the previous meeting had been actioned as detailed in the report.
- 2.4.** Members noted the matters arising report.

3. Chair and Chief Executive's report

- 3.1.** The Chair gave an overview of her engagement with key stakeholders and her attendance at decision-making committees of the Authority, noting that it had been a busy period since the last Authority meeting.
- 3.2.** The Chair informed members that she had attended the Scientific and Clinical Advances Advisory Committee (SCAAC) meeting which was held in early June.
- 3.3.** The Chair informed members that she had been involved in the shortlisting and interview process for the new Authority members (one lay and one professional). Recommendations have been made regarding appointable candidates and are awaiting Ministerial approval.
- 3.4.** Members were informed that the advert for the Chair position would be published week commencing 6 July and were encouraged to share the advert.
- 3.5.** The Chair informed members that she and the Chief Executive had attended the annual accountability meeting; this was a productive meeting and the HFEA is held in relatively high esteem by DHSC. Discussions had been held on the HFEA's law reform proposals and how these could be taken forward.
- 3.6.** The Chair highlighted the HFEA all-staff event held in late June, noting its value in bringing colleagues together for team-building.
- 3.7.** Concluding, the Chair informed members that together with senior executives she had attended a meeting with the MHRA AI Commission.
- 3.8.** The Chief Executive informed members that he had attend the Audit and Governance Committee meeting held in June and that this meeting had considered the year-end reports from the Government Internal Audit Agenda and the Annual Report and Accounts from the National Audit Office.
- 3.9.** The Chief Executive thanked the Chair and member, Anya Sizer, for attending the all-staff event and provided further insight in the work around refreshing the organisational values. Anya Sizer stated that it was a privilege to attend this event and reinforced what a unique organisation the HFEA is with dedicated, good staff.
- 3.10.** The Chief Executive informed members that he had attended the ALB Chairs and Chief Executives meeting with discussions being held on shared services.

Decision

- 3.11.** Members noted the Chair and Chief Executive's report.
-

4. Committee Chairs' report

- 4.1.** The Chair introduced the report and invited Committee Chairs to add any other comments to the presented report.
- 4.2.** The Statutory Approvals Committee (SAC) Chair (Frances Flinter) stated that the committee continues to meet monthly and the paper before the Authority includes a summary from the April and May meetings.
- 4.3.** The most recent SAC meeting was held earlier this week and had been chaired by Tim Child, this meeting will be reported on at the September Authority Meeting.
- 4.4.** The SAC Chair spoke of the comprehensive paperwork that the committee receives for each meeting with a report from Genetic Alliance representing patient's viewpoints. Together this allows the committee to make well informed decisions.
- 4.5.** The Audit and Governance Committee (AGC) Chair (Catharine Seddon) informed members that the AGC met on 16 June. They had received the annual opinion rating from GIAA, which was 'moderate'. Following discussions GIAA had agreed to revise the direction of travel rating to reflect the improved way of working and progress made on closing off audit recommendations.
- 4.6.** The AGC held a frank discussion with GIAA on what might make the internal audit provision better value, but the HFEA confirmed it will be going out to tender for this service.
- 4.7.** The AGC noted that only historic DSPT audit recommendations are outstanding, with all other audit recommendations closed. The AGC will consider the outstanding recommendations later in the year.
- 4.8.** The AGC Chair informed the Authority that the meeting had received a comprehensive report on the Phoenix Programme, noting that the go-live date had been extended by six weeks and a lessons learnt exercise is already being complied.
- 4.9.** AGC had discussed the revised Strategic Risk Register and asked that the risk of not taking up opportunities arising from AI be its own risk in a future revision rather than being a sub-risk. The AGC had also asked the Executive to capture the risk around the growth of the unregulated sectors and the mitigations which the HFEA had put in place, especially regarding communications.
- 4.10.** The AGC held a detailed discussion on the draft Annual Report and Accounts and agreed to recommend to the Authority that the Accounting Officer be authorised to sign these. The AGC Chair commented that the audit report from KPMG was extremely positive with just one audit recommendation. The AGC Chair praised the HFEA team for this achievement and their hard work.
- 4.11.** Closing, the AGC Chair stated that the bi-annual HR update report was extremely positive and noted that the time that the HFEA takes to fill vacancies is much shorter than the public sector average.
- 4.12.** In response to a question, the Chief Executive explained that there was great public and media interest in sperm donation taking place outside of licensed clinics. He explained the difficulties

and frustration in tackling unregulated donations and the reluctance of the police and social media platforms to enforce the law. He reiterated that sperm donation outside of licensed clinics is illegal under the HFE Act.

- 4.13.** The AGC Deputy Chair spoke of the transparent reporting by the IT team on the Phoenix Programme and the assurance and degree of confidence this provided to the committee.
- 4.14.** The Chief Executive reminded the Authority that there are two elements to the Phoenix Programme, the first being the movement of the HFEA's records from the old CM system to SharePoint and the second element moving Epicentre to a different platform. He cautioned that end-to-end testing of the second element may encounter unknown problems but he would keep the AGC apprised.
- 4.15.** The Scientific and Clinical Advances Advisory Committee (SCAAC) Chair (Tim Child) informed members that SCAAC had held its virtual meeting on 3 June and the [meeting papers](#) are available on the HFEA website.
- 4.16.** SCAAC had discussed emerging technologies in embryo and gamete testing, including genetic testing of sperm, microfluidic device – based sperm selection and AI driven sperm selection.
- 4.17.** SCAAC had discussed the impact of microbiome on fertility and fertility treatment outcomes. SCAAC had last considered this topic in June 2025 and the more recent discussion looked at the research which emphasises the complex, multi-factorial nature of the relationship between microbial composition in the female reproductive tract and reproductive success.
- 4.18.** SCAAC had discussed two add-on ratings and agreed that microbiome testing should be rated 'grey' due to lack of evidence and sperm DNA fragmentation testing should be rated 'red' due to safety concerns of harm from surgical procedure.
- 4.19.** SCAAC had reviewed an application for authorised use of in vitro maturation for oocytes and agreed that this did not fit within the scope of the existing authorised process and therefore a new process application was required.
- 4.20.** The SCAAC Chair reminded members that the HFEA will host its annual horizon scanning meeting next week at [ESHRE 2026](#) and feedback on this will be brought to the Authority in September.
- 4.21.** A member commented how reassuring the work of SCAAC is for patients, especially with regard to the review of add-ons, they questioned how patients could access this important work and whether the HFEA promotes this work to patient organisations.
- 4.22.** The SCAAC Chair responded that the information on [treatment add-ons](#) on the HFEA website is written for non-professionals. SCAAC decisions regarding treatment add-ons is very transparent with all papers, including the decision tree and meeting minutes, being published on the HFEA website.
- 4.23.** The Chair informed members that the HFEA would be hosting a session on the past, present and future of fertility regulation at ESHRE 2026.
- 4.24.** The Chair referred to a recent article in Nature regarding [base editing](#) of embryos and spoke of developments in the fertility landscape and how important the work of the HFEA is.
- 4.25.** The SCAAC Chair responded that Kathy Niakan had previously presented to SCAAC on this subject and the committee has a watching brief on this subject.

- 4.26.** The Chair thanked the Committee Chairs for the reports and expressed thanks to the committee members and the staff who service the various committees for their hard work. The Chair stated that committee papers and minutes are published on the [HFEA](#) website.

Decision

- 4.27.** Members noted the Committee Chairs' reports.
-

5. Performance Report

- 5.1.** The Chief Executive introduced the performance report and commented that whilst it is too early in the year to see trends, performance in May 2026 was good with ten KPIs rated Green, three Neutral, four Amber and two Red.
- 5.2.** The Chief Executive informed members that the sickness absence KPI remains Green with no long-term absence.
- 5.3.** Continuing, the Chief Executive said that whilst the turnover indicator was slightly above the threshold at 16.5% it was manageable and followed the cycle of natural movement of staff moving on for career progression and promotion, which as a small organisation the HFEA is limited in offering.

Strategy and Corporate Affairs

- 5.4.** The Director of Strategy and Corporate Affairs referred to the upcoming [ESHRE 2026](#) and reiterated the HFEA's activities at this event.
- 5.5.** The Director of Strategy and Corporate Affairs noted the [British Fertility Society](#) (BFS) Study Week, which is being held in September, which includes a joint BFS/HFEA day.
- 5.6.** Members were informed of parliamentary activity including [the debate in the House of Lords](#) on the adequacy of the law on the regulation of fertility treatment, led by Baroness Deech and supported by Baroness Nargund. Several of the HFEA's [law reform proposals](#) were quoted in this debate.
- 5.7.** The Director of Strategy and Corporate Affairs referred to the [BBC Wales](#) programme on unregulated sperm donation and the associated press articles this generated. The updated [FAQs relating to unregulated sperm donation](#) on the HFEA's website achieves an average 100 view per day, but when the programme aired this peaked at 1,000 views a day.
- 5.8.** The Director of Strategy and Corporate Affairs informed members that the [Fertility treatment 2024: trends and figures](#) report was published recently and the dashboard updated accordingly. She thanked the staff who were involved in the production of this report. The report had not received as much coverage as previously years but had some coverage in the media and good take up on social media, as well as views on the HFEA website.
- 5.9.** Continuing, the Director of Strategy and Corporate Affairs informed members that the team is working on the embryo testing guidelines and the state of the sector report. In response to a question, she confirmed that the embryo testing guidelines will be coming to the September Authority meeting.
- 5.10.** Several members congratulated the Director of Strategy and Corporate Affairs for her participation in the BBC Wales programme. The Director of Strategy and Corporate commented

that the law is very clear and that the only legal way to donate sperm is as at a HFEA licenced clinic.

Compliance and Information

- 5.11.** The Director of Compliance and Information informed members that the inspection KPIs have started well for the year.
- 5.12.** Regarding the post inspection feedback survey, a new process was started in December 2025 to increase completion. The process is now managed by the business support team and awareness has been raised through clinic focus and leaflets being handed out during inspection close out meetings. In the past six months there has been an increase in returns and the sector will be encouraged to keep providing feedback.
- 5.13.** The Director of Compliance and Information informed members that the feedback from these surveys is discussed at the monthly inspectors meeting and actions taken as required.
- 5.14.** The Director of Compliance and Information informed members that both the OTR KPIs were rated 'red' and this was due to planned annual leave of the OTR team.
- 5.15.** The Director of Compliance and Information stated that the current OTR targets are no longer relevant, as the waiting list has decreased significantly and most of the OTRs on the waiting list are being actively worked on. A review of the KPIs is currently in progress and it is anticipated that these will focus on waiting times.
- 5.16.** Members were informed that whilst the average waiting time for applications has decreased to around a month in May 2026, this can fluctuate as more complex OTRs are closed.
- 5.17.** The Director of Compliance and Information stated the register audit schedule had been set for the financial year and 12 clinics had been selected for inspection. The Director of Compliance and Information explained that those clinics with the highest error rates are shortlisted for audit and explained the other factors used to choose which clinics should be audited.

Finance, Planning and Technology

- 5.18.** The Director of Finance, Planning and Technology informed members that the Planning and Governance team had been preparing for new member recruitment, including updating the required induction documents.
- 5.19.** The Director of Finance, Planning and Technology stated that there has been an increase in the number of corporate complaints and data requests recently and the team has been logging and responding to these. The team will continue to monitor volumes and keep the relevant policies and processes under review.
- 5.20.** Members were informed that the recruitment of two key IT roles is underway and these roles are part of the HFEA's IT plan and will bring additional expertise and resilience to the team.
- 5.21.** The Director of Finance, Planning and Technology informed members that this year's DSPT audit had been completed and there had been several important improvements delivered this year, but a few key actions remain outstanding. These are a priority and will be addressed once Phoenix has been completed and the additional IT resources recruited.
- 5.22.** The focus for the Finance Team has been the preparation of the Annual Report and Accounts which will be discussed at a later agenda item.

- 5.23.** At the May 2026 Authority the pre-audit deficit for 2025-26 of £299,000 was reported. During the audit there were several adjustments put through the accounts, which changed this position. In particular, significant revisions to estimated income relating to three clinics that have enduring gaps in their PRISM data submissions had to be made.
- 5.24.** These changes moved the HFEA's deficit to £875,000, although the accounts show a deficit of around two million because they do not include Grant-in-Aid in the bottom line. The Director of Finance, Planning and Technology informed members that discussions had been held with the Department about this changing position, who were supportive of decisions relating to income recognition and are able to absorb this additional deficit.
- 5.25.** Regarding 2026-27 spend it is too early in the year to get any indications of divergence from the budget but a full review of year-end forecast will be undertaken at the end of Q1.
- 5.26.** In response to a question, the Director of Finance, Planning and Technology confirmed that the volume of corporate complaints and information requests has increased. He noted that in some cases these requests are interconnected, with the same individual progressing through several processes. For example, a clinical complaint may develop into a corporate complaint and then result in a data protection or information request, increasing the overall workload associated with a single case.
- 5.27.** The Chief Executive noted that no clear trends had been identified in the nature of complaints received. Members were reminded that, as a public body, the HFEA must comply with statutory requirements for the retention and processing of information. The Chief Executive advised that, should the volume of requests continue to increase, it may be necessary to review existing policies to ensure requests can be managed efficiently without placing additional pressure on staff resources. It was also noted that public bodies operate within agreed staffing levels and cannot exceed their authorised headcount.
- 5.28.** The Head of Planning and Governance clarified that the HFEA has two complaints policies. The Clinical Complaints Policy covers complaints about fertility treatment at a HFEA licensed clinic; the Corporate Complaints Policy covers complaints about the work of the HFEA and the way in which we have exercised our statutory duties (this includes data protection complaints).
- 5.29.** The Head of Planning and Governance confirmed that an increasing number of corporate complaints and information requests appear to have used generative AI to frame and articulate their complaint or request.
- 5.30.** A member spoke of the opportunity that complaints provide for learning and maximising learning opportunities for the organisation. They commented that the advent of AI means that people feel more empowered to complain and take action.
- 5.31.** The Chief Executive responded that when the HFEA has made an error they are open and honest with sharing that with the complainant.

Decision

- 5.32.** Members noted the performance report.

6. Annual Report and Accounts

- 6.1. The Director of Finance, Planning and Technology stated that AGC recommended that the Chief Executive, as Accounting Officer, sign off the Annual Governance Statement at its meeting on 16 June. AGC also recommend the Annual Report and Accounts for approval by the Authority.
- 6.2. Due to the extremely tight deadline for certification and publication of the HFEA's Annual Report and Accounts approval from the Authority had been sought out of committee, via email. He thanked members for responding so promptly to this email and unanimous approval had been given on 19 June 2026.
- 6.3. The accounts were certified on 29 June 2026 and were laid in Parliament on 30 June. The Director of Finance, Planning and Technology thanked the HFEA's Finance Team for their work in preparing the Accounts and Annual Report.

Decision

- 6.4. Members noted the verbal report and that the HFEA's Annual Report and Accounts had been approved out of committee, via email, and successfully laid in Parliament.

7. Strategic Risk Register and Risk Appetite Statement

- 7.1. The Risk and Business Planning Manager introduced this agenda item and reminded members that the Authority reviews the Strategic Risk Register (SRR) twice a year, with detailed consideration of the SRR being undertaken by the AGC. The AGC had discussed the SRR at its June meeting.
- 7.2. The Risk and Business Planning Manager informed the members that the AGC reviewed the Risk Appetite Statement in both February and June 2026, with minor amendments presented for the Authority's approval.
- 7.3. The AGC Chair informed members that the AGC had recommended to the Executive that the sub-risk around the benefits from both new systems and AI not being realised should be its own risk in the next iteration of the SRR.
- 7.4. The Deputy AGC Chair spoke of the mitigations which the HFEA undertakes regarding the unregulated sector and how these had been articulated in the SRR.
- 7.5. In response to a question the Chief Executive confirmed that the risk regarding reputational risk had not been removed, but duplication throughout the SRR had been removed.

Decision

- 7.6. The Authority approved:
 - the updated Strategic Risk Register
 - the updated Risk Appetite Statement.

8. Register Research Panel (RRP) Annual Report

- 8.1. The Chair introduced the agenda item and informed the Authority that they will be sitting as the Oversight Committee to consider this item.

- 8.2.** The Head of Research and Intelligence introduced the paper and reminded members that the HFE (Disclosure of Information for Research Purposes) Regulations 2010 allow the disclosure of information for research purposes, and that the Authority has delegated authorisation for this to the Register Research Panel (RRP).
- 8.3.** The Head of Research and Intelligence updated the recent [Fertility treatment 2024: trends and figures](#) publication and updates to the HFEA dashboard. The next planned publication using HFEA register data is a report on egg freezing in fertility treatment.
- 8.4.** The Senior Research Manager informed the Authority of recently approved RRP projects and peer-reviewed papers using both RRP-approved datasets and the anonymised register.
- 8.5.** The Senior Research Manager spoke of the activities undertaken to increase the visibility of the HFEA's data for research including the [HFEA Data Research Update Newsletter](#) which now has over 270 subscribers with a high 55% open rate.
- 8.6.** The Senior Research Manager informed members that as part of the HFEA's strategic aim to increase the visibility of its data for research, the HFEA had engaged with the [Health Data Research \(HDR\) UK Gateway](#) to host a link to the HFEA data research website on their online platform.
- 8.7.** The Senior Research Manager informed members of the new ways that had been set up to engage with researchers and find out information about who wants HFEA data, where they are from and how they want to use the data. An anonymised dataset enquiry form was launched in January 2026 to address this.
- 8.8.** The Senior Research Manager commented that the team are looking at new options for the anonymised resources. This has included discussions with other data organisations with similar datasets to understand their current practices. Many of these organisations such as UK Biobank, UKHSA and NHS England are using or developing synthetic datasets and Trusted Research Environment platforms (TREs) to allow researchers access to datasets.
- 8.9.** TREs are viewed as best practice for providing access to data in a safe and secure manner but the Senior Research Managers cautioned that these have significant cost implications that the HFEA will need to consider before any implementation.
- 8.10.** A member questioned whether funding for TREs had been discussed with the DHSC as it aligns with the Government's policies regarding data. The Head of Research and Intelligence responded that more work needs to be done on the options available to the HFEA but then we could raise with the Department.
- 8.11.** A member spoke of the research being conducted by private organisations and questioned whether any applications had been made to use the HFEA's data. The Director of Strategy and Corporate Affairs responded that applications from private companies had been received by the RRP and she referred to the 2010 regulations which govern how and to whom this data can be released. The Head of Research and Intelligence commented that applications from private organisations would be welcomed, but under the 2010 regulations they must be UK based.
- 8.12.** A member questioned whether the list of publications, annexed to the paper, is shared wider with the sector such as via Clinic Focus as it may benefit resident doctors who are looking for projects and might not be aware of the rich source of data that the HFEA holds. The Head of

Research and Intelligence responded that there had been articles in Clinic Focus previously and the HFEA attends several Conferences to promote the use of HFEA data.

- 8.13.** Members discussed the growth and interest in life sciences and the Government's innovation agenda and how the HFEA's data could help stimulate the Government's growth agenda. The Chief Executive cautioned that the 2010 regulations sets out what the HFEA can charge for making its data available and the cost doesn't cover the cost of the work. He would not want to create a demand which cannot be met from current resources.
- 8.14.** A member spoke in support TREs and provided their own personal experience in developing one and highlighted some of the challenges encountered during the project. He cautioned the amount of time required to implement a TREs and that the HFEA might want to consider using an established one which aligns with the HFEA's principles.
- 8.15.** A member questioned whether the patient organisation groups get updates on the research projects carried out using the HFEA's data.
- 8.16.** The Chair drew the discussion to a close and thanked the Head of Research and Intelligence and the Senior Research Manager for their comprehensive paper and informative presentation on the use of the HFEA's data.

Decision

- 8.17.** The Authority, sitting as the Oversight Committee, noted the Annual Report of the Register Research Panel.

9. SoHO Regulations update

- 9.1.** The Regulatory Policy Manager introduced the paper and informed members that the [Regulation on standards of quality and safety for substances of human origin intended for human application](#) ('the SoHO Regulation') will come into force in August 2027.
- 9.2.** The Regulation covers gametes and embryos, as well as other substances of human origin (SoHO) which are outside of the HFEA's remit. Following the UK's exit from the European Union and as per the terms of the Windsor Framework, the SoHO Regulation will apply to Northern Ireland (NI) only and not to Great Britain (GB).
- 9.3.** As the UK-wide regulator of fertility treatment and the Competent Authority for NI, the HFEA has a responsibility to comply with these Regulations as they relate to fertility treatment and to ensure that centres in NI do the same. At present there are three HFEA licensed fertility clinics in NI.
- 9.4.** The Regulatory Policy Manager spoke of the impact of the SoHO Regulation on clinics in NI and the HFEA. She stated that it is the HFEA's wish to avoid any unnecessary regulatory burden for NI clinics and she explained the main changes for clinics in NI
- 9.5.** The Regulatory Policy Manager commented that the SoHO Regulation increases divergence between NI and GB, unless any changes are made to UK law. The DHSC were currently considering this issue.
- 9.6.** The Regulatory Policy Manager explained the two options in the paper:
 - **Option one:** Only recommend changes to UK law that align with existing HFEA law reform proposals, as set out in annex A of the paper.

- **Option two:** Recommend one or more of the changes (a-h) to UK law set out in Annex B of the paper, in addition to existing HFEA law reform proposals.

- 9.7.** The Regulatory Policy Manager explained the next steps leading up to the SoHO Regulation implementation date of 7 August 2027.
- 9.8.** In response to a question the Director of Strategy and Corporate Affairs commented that it would not be possible to implement the HFEA's proposals for law reform via the implementation of the SoHO Regulation.
- 9.9.** Members were supportive of option two. In response to a question the Chief Executive confirmed that work and other priorities would not be dropped to implement the SoHO Regulation and it does not weaken the HFEA's proposals for law reform.

Decision

- 9.10.** The Authority unanimously agreed to recommend option two: recommend one or more of the changes (a-h) to UK law set out in Annex B of the paper, in addition to existing HFEA law reform proposals.

Action

- 9.11.** Executive to implement option two regarding SoHO Regulation.

10. Any other business

- 10.1.** A member informed the Authority that he had attended the first NHS IVF Clinics Conference and provided an overview of the presentations and discussions. He commented that it was a very worthwhile conference and he asked that the HFEA be invited to attend or speak at the next one.
- 10.2.** The Chair thanked everyone for their active participation in the meeting and for the high quality of papers before the Authority.
- 10.3.** There being no further items of any other business, the Chair closed the meeting and reminded members that the next full Authority meeting is being held on 23 September. Details of this meeting, including how to request to observe, is posted on the HFEA website. The Chair wished everyone a good summer break.

Chair's signature

I confirm this is a true and accurate record of the meeting.

Signature



Chair: Julia Chain

Date: 23 September 2026